CGON vs. FUSN, DNA, NVAX, INBX, BEAM, SANA, ADMA, NMRA, KYMR, and TARS
Should you be buying CG Oncology stock or one of its competitors? The main competitors of CG Oncology include Fusion Pharmaceuticals (FUSN), Ginkgo Bioworks (DNA), Novavax (NVAX), Inhibrx (INBX), Beam Therapeutics (BEAM), Sana Biotechnology (SANA), ADMA Biologics (ADMA), Neumora Therapeutics (NMRA), Kymera Therapeutics (KYMR), and Tarsus Pharmaceuticals (TARS). These companies are all part of the "biological products, except diagnostic" industry.
CG Oncology (NASDAQ:CGON) and Fusion Pharmaceuticals (NASDAQ:FUSN) are both small-cap medical companies, but which is the superior stock? We will compare the two companies based on the strength of their valuation, dividends, profitability, earnings, risk, analyst recommendations, community ranking, media sentiment and institutional ownership.
CG Oncology presently has a consensus target price of $63.75, suggesting a potential upside of 112.64%. Fusion Pharmaceuticals has a consensus target price of $20.25, suggesting a potential downside of 5.86%. Given CG Oncology's stronger consensus rating and higher possible upside, equities research analysts plainly believe CG Oncology is more favorable than Fusion Pharmaceuticals.
CG Oncology has higher earnings, but lower revenue than Fusion Pharmaceuticals.
In the previous week, CG Oncology had 8 more articles in the media than Fusion Pharmaceuticals. MarketBeat recorded 8 mentions for CG Oncology and 0 mentions for Fusion Pharmaceuticals. CG Oncology's average media sentiment score of 0.33 beat Fusion Pharmaceuticals' score of 0.00 indicating that CG Oncology is being referred to more favorably in the media.
26.6% of CG Oncology shares are owned by institutional investors. Comparatively, 72.9% of Fusion Pharmaceuticals shares are owned by institutional investors. 7.8% of Fusion Pharmaceuticals shares are owned by company insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a stock is poised for long-term growth.
Fusion Pharmaceuticals received 33 more outperform votes than CG Oncology when rated by MarketBeat users. However, 80.00% of users gave CG Oncology an outperform vote while only 64.06% of users gave Fusion Pharmaceuticals an outperform vote.
CG Oncology has a net margin of 0.00% compared to Fusion Pharmaceuticals' net margin of -4,136.55%. CG Oncology's return on equity of 0.00% beat Fusion Pharmaceuticals' return on equity.
Summary
CG Oncology beats Fusion Pharmaceuticals on 11 of the 15 factors compared between the two stocks.
Get CG Oncology News Delivered to You Automatically
Sign up to receive the latest news and ratings for CGON and its competitors with MarketBeat's FREE daily newsletter.
This chart shows the number of new MarketBeat users adding CGON and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.
This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.
CG Oncology Competitors List
Related Companies and Tools
